Supplement Forms/Alternate Names
Isoflavones are water-soluble chemicals found in many plants. In this article, we will discuss a group of isoflavones that are phytoestrogens, meaning that they cause effects in the body somewhat similar to those of estrogen. The most investigated phytoestrogen isoflavones, genistein and daidzein, are found both in soy products and the herb red clover. Soy additionally contains glycitein, an isoflavone that is more estrogenic than genistein and daidzein, but is usually present in relatively low amounts. Red clover also contains two other isoflavones: biochanin (which can be turned into genistein) and formonenetin (which can be turned into daidzein).
Certain cells in the body have estrogen receptors, special sites that allow estrogen to attach. When estrogen attaches to a cell’s estrogen receptor, estrogenic effects occur in the cell. Isoflavones latch onto estrogen receptors too, but produce weaker estrogenic effects. This leads to an interesting two-part action. When there is not enough estrogen in the body, isoflavones can stimulate cells with estrogen receptors and partly make up for the deficit. However, when there is plenty of estrogen, isoflavones may tend to block real estrogen from attaching to estrogen receptors, thereby reducing the net estrogenic effect. This may reduce some of the risks of excess estrogen (for example, breast and uterine cancer) while still providing some of estrogen's benefits (such as, preventing osteoporosis).
Isoflavones also appear directly to reduce estrogen levels in the body, perhaps by fooling the body into thinking that it has plenty of estrogen.
Isoflavones are widely thought to be the active ingredients in soy products. However, growing evidence suggests that there are other active ingredients as well, such as proteins, fiber, and phospholipids.
Although isoflavones are not essential nutrients, they may help reduce the incidence of several diseases. Thus, isoflavones may be useful for optimum health, even if they are not necessary for life like a classic vitamin.
Roasted soybeans have the highest isoflavone content: about 167 mg for a 3.5-ounce serving. Tempeh (a cake of fermented soybeans) is next, with 60 mg, followed by soy flour with 44 mg. Processed soy products such as soy protein and soy milk contain about 20 mg per serving. The same isoflavones found in soy are also contained in certain red clover products.
When purified isoflavones from red clover or soy are used, the dose generally ranges from about 40 mg to 80 mg daily. This is considerably higher than the average isoflavone intake in Japan, which is about 28 mg daily.109 (Post-menopausal Japanese women may consume closer to 50 mg daily.17)
There are three major isoflavones found in soy: genistein, daidzein, and glycitein. Each of these isoflavones can occur in two types or states. The first type, predominant in raw soy products, is called an “isoflavone glycoside.” In an isoflavone glycoside, the isoflavone is attached to a sugar-like substance known as a “glycone.” The second type, predominant in fermented soy products, is called an “isoflavone aglycone.” These consist of isoflavones without a glycone attached, and are also called “free isoflavones.” Since isoflavone aglycones are the most pure form of isoflavones, it has been hypothesized (but not proven) that they are more effective than other forms.193
Soy products are known to improve cholesterol profile, but isoflavones may not be the active cholesterol-lowering ingredient in soy.110,195 Isoflavones may, however, improve other measures linked to cardiovascular risk, such as levels of blood sugar, insulin, and fibrinogen.147,148,190
According to some but not all studies, soy protein or concentrated isoflavones from soy or red clover may slightly reduce menopausal symptoms, such as hot flashes and vaginal dryness.6,16,42-50,90,106,111-116,166-167,192
However, isoflavones have failed to prove effective for the hot flashes that often occur in breast cancer survivors.91,107,117,149
There is conflicting evidence regarding whether soy or isoflavones may be helpful for preventing osteoporosis, but on balance the evidence suggests a modest beneficial effect.22-30,118-124,150,151,191
One study tested a purified soy isoflavone product (technically, isoflavone aglycones, as described above) for treatment of aging skin.187 In this double-blind trial, 26 Japanese women in their late 30s and early 40s were either given placebo or 40 mg daily of soy isoflavone aglycones for 12 weeks. Researchers monitored two types of wrinkles near the eye: “fine” wrinkles and “linear” wrinkles. The results indicated that use of the soy product significantly reduced “fine” wrinkles as compared to placebo. (Effects on “linear” wrinkles were not significant.) As a secondary measure, researchers also analyzed skin elasticity, and found an improvement in the women given the isoflavones as compared to those given placebo. Note: This was much too small a study for its results to be taken as reliable.
A double-blind study performed in China found that use of a soy isoflavone supplement improved blood sugar control in healthy post-menopausal women.184
In a small double-blind trial, use of soy isoflavones appeared to reduce some symptoms of premenstrual syndrome PMS.169 A very small study found hints that soy isoflavones might help reduce buildup of abdominal fat.185
Observational studies hint that soy may help prevent breast and uterine cancer in women.9-15 If this connection is real and not a statistical accident (observational studies are notorious for falling prey to statistical accidents), the explanation may lie in the estrogen-like action of soy isoflavones. As noted above, isoflavones decrease the action of regular estrogen by blocking estrogen receptor sites, and may also reduce levels of circulating estrogen.1,2,79-82,92-94,168 Since estrogen promotes breast and uterine cancer, these effects could help prevent breast cancer. Soy also appears to lengthen the menstrual cycle by a few days,70,78,92 and this too would be expected to reduce breast cancer risk. However, only a large, long-term intervention trial could actually show that soy or isoflavones reduce breast and uterine cancer risk, and one has not been performed.
Observational studies also hint that soy might help prevent prostate cancer in men. Men have very low levels of circulating estrogen, so the net effect of increased soy consumption might be to increase estrogen-like activity in the body. Since real estrogen is used as a treatment to suppress prostate cancer, perhaps the mild estrogen-like activity of isoflavones has a similar effect. Isoflavones might also decrease testosterone levels and alter ratios of certain forms of estrogen, both of which which would be expected to provide benefit.153,194
In one double-blind study, men with early prostate cancer were given either isoflavones or placebo, and their PSA levels were monitored.125 (PSA is a marker for prostate cancer, with higher values generally showing an increased number of cancer cells.) The results did show that use of isoflavones (60 mg daily) slightly reduces PSA levels. Whether this meant that soy actually slowed the progression of the cancer or simply lowered PSA directly is not clear from this study alone. However, in another study of apparently healthy men (not known to have prostate cancer), soy isoflavones at a dose of 83 mg per day did not alter PSA levels.126 Taken together, these two studies provide some direct evidence that soy isoflavones may be helpful for treating or preventing prostate cancer, but the case nonetheless remains highly preliminary.
A review of 8 randomized trials evaluated soy foods or soy isoflavones for prevention or treatment of prostate cancer in 1,025 men. Soy isoflavones were associated with reduced risk of prostate cancer in 2 trials of 122 men. Although 2 of the trials showed promise, it was difficult to draw strong conclusions because of small study populations and differeing soy preparations and dosages across all trials.208
One study failed to find that soy protein with isoflavones improved general quality of life (health status, depression, and life satisfaction) in post-menopausal women.155 Soy isoflavones have also failed to prove effective for reducing levels of homocysteine.171
What Is the Scientific Evidence for Isoflavones?
Numerous studies have found that soy can reduce blood cholesterol levels and improve the ratio of LDL ("bad") versus HDL ("good") cholesterol.32,33
Although it was once thought that isoflavones are the ingredients in soy responsible for improving cholesterol profile, on balance, current evidence suggests otherwise.7,31,34-41,83,108,109-110,117119,120,124,156,172,205,207 Non-isoflavone constituents of soy, such as proteins, fiber, and phospholipids, may be equally or perhaps even more important than the isoflavones in soy.96,127,195
It is also possible that the exact types of isoflavones in a particular product made a difference. One study of red clover isoflavones found evidence that biochanin but not formononetin can reduce LDL cholesterol.128
Another study found that soy products may at times have an unusual isoflavone profile, containing high levels of the isoflavone glycitein rather than the more usual genistein and daidzein.84 Glycitein could be inactive regarding cholesterol reduction.
Finally, some evidence hints that soy isoflavones may be only effective for reducing cholesterol when it is converted by intestinal bacteria into a substance called equol.129,189 It appears that only about one-third of people have the right intestinal bacteria to make equol.
Although study results are not entirely consistent, the balance of the evidence suggests that isoflavones from soy may be helpful for symptoms of menopause, especially "hot flashes."
Improvements in hot flashes, as well as other symptoms, such as vaginal dryness, have been seen in many studies of soy, mixed soy isoflavones, isoflavone aglycones, or genistein alone.20,21,43-47,106,130-2,157,181,192,193,206 However, the effects have been slight or non-existent in other studies.198 At least two studies found that people who are equol producers (see previous section) may experience greater benefits.157,200
Cognitive function and visual memory were significantly improved in a review of 10 randomized trials with 1,024 postmenopausal women. Soy isoflavones (60 mg-160 mg daily for 6 weeks to 30 months) were compared to placebo in all trials. However several factors, such as age at the start of treatment, location of treatment, and treatment duration may affect the overall success of the supplement.209
The herb Pueraria mirifica, which also contains a number of isoflavones, has also shown some benefit for menopausal symptoms.196,197
However, several other studies have failed to find benefit with whole soy or concentrated soy isoflavones.16,48-50,90,96,173 Another study failed to find benefit with a mixture of soy isoflavones and black cohosh.174
Furthermore, in double-blind, placebo-controlled trials, soy or purified isoflavones failed to reduce hot flashes among survivors of breast cancer.91,107,117,159
What can one make of this mixed evidence? The problem here is that placebo treatment has a strong effect on menopausal symptoms. In such circumstances, statistical noise can easily drown out the real benefits of a treatment under study. Estrogen is so powerful for hot flashes and other menopausal symptoms that its benefits are almost always clear in studies; most likely, soy or concentrated isoflavones have a more modest effect, not always seen above the background.
Estrogen has a powerfully protective effect on bone. Study results on whether isoflavones have the same effect have produced inconsistent results.117-124,160,161,175,191 On balance, it is probably fair to summarize current evidence as indicating that isoflavones (either as soy, genistein, mixed isoflavones, or tofu extract) have at least a modestly beneficial effect on bone density.
The best evidence is for genistein taken alone. In a 24-month, double-blind study of 389 postmenopausal women with mild bone loss, use of genistein at a dose of 54 mg daily significantly improved bone density as compared to placebo. (All participants were additionally given calcium and vitamin D.)191
However, it is not clear that isoflavones consumed in the diet, even at high concentrations, is beneficial. For example, in a placebo-controlled study involving 237 healthy women in the early stages of menopause, the consumption of isoflavone-enriched foods (providing an average of 110 mg isoflavone aglycones daily) for 1 year had no affect on bone density or metabolism.199
Interestingly, one small, but long-term study suggests that progesterone cream (another treatment proposed for use in preventing or treating osteoporosis) may decrease the bone-sparing effect of soy isoflavones.118
Bone is always subject to two influences: bone building and bone breakdown. Estrogen primarily works by reducing the bone breakdown part of the equation, thereby leading to a net result of increased bone growth. Growing evidence suggests that isoflavones act on both sides of this equation, directly stimulating new bone creation while at the same time slowing bone breakdown.19,63,64,183
There is mixed evidence that isoflavones are more effective for osteoporosis in people who have the intestinal bacteria to produce equol.176,199
In a 24-week, double-blind study, 49 women with menstrual migraines ( migraine headaches associated with the menstrual cycle) received either placebo or a combination supplement containing soy isoflavones and extracts of dong quai and black cohosh.8 Beginning at the 20th week, use of the herbal supplement resulted in decreased severity and frequency of headaches as compared to placebo. However, it is not clear which of the ingredients in the combination was helpful. The authors of the study apparently considered black cohosh and dong quai as phytoestrogens, but the current consensus is that they do not belong in that category.
Studies in animals have found soy isoflavones essentially nontoxic.65 The long history of the use of soy as food in Asia would tend to suggest they are safe as well. Even though absolute safety cannot be assumed from historical consumption of soy as food, it is reassuring to note that researchers found no evidence of ill effects when they gave healthy postmenopausal women 900 mg of soy isoflavones a day for 84 consecutive days.202 In Japan, the maximum safe intake level of soy isoflavones has been set at a total of 70 to 75 mg daily (food plus supplement sources).
Still, concerns have been raised about estrogenic and other potential side effects of excessive soy isoflavone intake. Overall, the estrogenic effect of soy isoflavones in women appear to be fairly minimal.135 Nonetheless, it is not zero. According to most but not all studies, use of soy has enough of an estrogen-like effect to slightly alter the menstrual cycle and change levels of sex hormones in young women.70,78-82,92-94,136-138,177 Thus, some of the risks of estrogen could, in theory, apply to isoflavones as well.
For example, because estrogen can stimulate breast cancer cells, there are theoretical concerns that isoflavones may not be safe for women who have already had breast cancer. While isoflavones in general should have an anti-estrogenic effect by blocking real estrogen, some studies in animals have found evidence that, under certain circumstances, soy isoflavones might stimulate breast cancer cells.75-77 Studies directly examining the effects of isoflavones on human breast tissue have produced contradictory results.4,18,97,139. However, on balance, there is no convincing evidence that consuming moderate amounts of soy isoflavones (at levels typical of an Asian diet) increases the risk of breast cancer in healthy women or worsens the prognosis of women with breast cancer.203 Nevertheless, given the theoretical risk and the absence of large randomized trials investigating the safety of isoflavone supplements, prudence suggests that women who have had breast cancer, or are at high risk for it, should consult a physician before taking any isoflavone product.96
Estrogen also stimulates uterine cells, leading to an increased risk of uterine cancer. Most studies have found that isoflavones do not stimulate uterine cells.16,111,140,141,162,178, 181,190,204 However, one fairly large (365 participants) and long-term (5 years) study did find uterine stimulation in 3.37% of women on isoflavones and 0% of those on placebo.142 This could indicate a slightly increased risk of uterine cancer with high-dose isoflavone use.
Similarly, preliminary studies and reports have raised concerns that intensive use of soy products or isoflavones by pregnant women could exert a hormonal effect that impacts unborn fetuses.67,68 Use of soy formula by infants is also of concern along these lines, as an infant subsisting on soy formula has a relatively enormous isoflavone intake; on a per-weight basis, it may exceed the average Asian adult isoflavone intake by a factor of ten.
The drug tamoxifen blocks estrogen and is used to help prevent breast cancer recurrence in women who have had breast cancer. One animal study found that soy isoflavones might remove the benefit of tamoxifen treatment.163
One double-blind study of post-menopausal women found the use of red clover isoflavones at a dose of 80 mg daily for 90 days resulted in increased levels of testosterone.179 The potential significance of this is unclear. In men, isoflavones might decrease testosterone levels, but the effect appears to be slight at most.164,165
Other concerns relate to soy’s potential effects involving the thyroid gland. When given to individuals with impaired thyroid function, soy products have been observed to reduce absorption of thyroid medication.72,73,98 In addition, some evidence hints that soy isoflavones may directly inhibit the function of the thyroid gland (though perhaps only in people who are iodine deficient).71,99,100,143 To make matters more confusing, studies of healthy humans and animals given soy isoflavones or other soy products have generally found that soy either had no effect on thyroid hormone levels or actually increased levels.79,101-104,188 The bottom line: In view of soy’s complex effects regarding the thyroid, individuals with impaired thyroid function should not take large amounts of soy products except under the supervision of a physician.
While fears have been expressed by some experts that soy isoflavones might interfere with the action of oral contraceptives, one study of 36 women found reassuring results.69
Some evidence suggests that the isoflavone genistein might impair immunity. One study in mice found that injected genistein has negative effects on the thymus gland (an organ that is important for immunity) and also causes changes in the prevalence of various white blood cells consistent with impaired immunity.85 Although the genistein was injected rather than administered orally, the blood levels of genistein that these injections produced were not excessively high; they were comparable to (or even lower than) what occurs in children fed soy milk formula. In addition, there are several reports of impaired immune responses in infants fed soy formula.86-89 While it is too early to conclude that genistein impairs immunity, these findings are a potential cause for concern.
One observational study raised concerns that soy might impair mental function in adults.105 However, observational studies are far less reliable than clinical trials. Direct studies designed to test the potential effects of isoflavones on brain function, and lasting up to 12 months, have found either no effect or a slightly positive effect on brain function.96,144-146,154,158, 182 While this does not rule out a harmful long-term effect on cognition, it is reassuring.
There exists one case report in which soy isoflavone supplements caused migraine headaches in a man who had never experienced migraines before; presumably this was a highly individual reaction, such as an allergy.3 Similarly, while soy products are sometimes recommend for reducing blood pressure, there is also a well-documented case report in which use of high dose soy isoflavones caused extreme elevation in blood pressure in a woman participating in a scientific study (of soy isoflavones).180
Some researchers have raised concern that genistein may influence the ability of blood to clot properly. A placebo-controlled study involving 104 healthy women, however, found no evidence that the isoflavone genistein had any significant adverse effect on blood clotting.201
1. Nagata C, Kabuto M, Kurisu Y, et al. Decreased serum estradiol concentration associated with high dietary intake of soy products in premenopausal Japanese women. Nutr Cancer. 1997;29:228-223.
2. Nagata C, Naoyoshi T, Shizuyo I, et al. Effect of soymilk consumption on serum estrogen concentrations in premenopausal Japanese women. J Natl Cancer Inst. 1998;90:1830-1835.
3. Engel PA. New onset migraine associated with use of soy isoflavone supplements. Neurology. 2002;59:1289-1290.
4. Maskarinec G, Williams AE, Carlin L. Mammographic densities in a one-year isoflavone intervention. Eur J Cancer Prev. 2003;12:165-169.
5. Jones G, Dwyer T, Hynes K, et al. A randomized controlled trial of phytoestrogen supplementation, growth and bone turnover in adolescent males. Eur J Clin Nutr. 2003;57:324-327.
6. Burke GL, Legault C, Anthony M, et al. Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study. Menopause. 2003;10:147-153.
7. Blakesmith SJ, Lyons-Wall PM, George C, et al. Effects of supplementation with purified red clover ( Trifolium pratense) isoflavones on plasma lipids and insulin resistance in healthy premenopausal women. Br J Nutr. 2003;89:467-475.
8. Burke BE, Olson RD, Cusack BJ. Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharmacother. 2002;56:283-288.
9. Messina MJ, Persky V, Setchell KD, et al. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer. 1994;21:113-131.
10. Adlercreutz H, Mazur W. Phyto-oestrogens and western diseases. Ann Med. 1997;29:95-120.
11. Stoll BA. Eating to beat breast cancer: Potential role for soy supplements. Ann Oncol. 1997;8:223-225.
12. Day NE. Phyto-estrogens and hormonally dependent cancers. Pathol Biol. 1994;42:1090.
13. Barnes S, Peterson TG, Coward L. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J Cell Biochem Suppl. 1995;22:181-187.
14. Ingram D, Sanders K, Kolybaba M, et al. Case-control study of phyto-oestrogens and breast cancer. Lancet. 1997;350:990-994.
15. Goodman MT, Wilkens LR, Hankin JH, et al. Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol. 1997;146:294-306.
16. Penotti M, Fabio E, Modena AB, et al. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril. 2003;79:1112-1117.
17. Somekawa Y, Chiguchi M, Ishibashi T, et al. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol. 2001;97:109-115.
18. Petrakis NL, Barnes S, King EB, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and post-menopausal women. Cancer Epidemiol Biomarkers Prev. 1996;5:785-794.
19. Morabito N, Crisafulli A, Vergara C, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res. 2002;17:1904-1912.
20. Upmalis DH, Lobo R, Bradley L, et al. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause. 2000;7:236-242.
21. Han KK, Soares JM, Haidar MA et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol. 2002;99:389-394.
22. Potter SM, Baum JA, Teng H, et al. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr. 1998;68(suppl 6):1375S-1379S.
23. Alekel DL, St. Germain A, Peterson CT, et al. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr. 2000;72:844-852.
24. Harrison E, Adjei A, Ameho C, et al. The effect of soybean protein on bone loss in a rat model of postmenopausal osteoporosis. J Nutr Sci Vitaminol (Tokyo). 1998;44:257-268.
25. Fanti O, Faugere MC, Gang Z, et al. Systematic administration of genistein partially prevents bone loss in ovariectomized rats in a nonestrogen-like mechanism [abstract]. Am J Clin Nutr. 1998;68(suppl):1517S-1518S.
26. Arjmandi BH, Alekel L, Hollis BW, et al. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr. 1996;126:161-167.
27. Fanti P, Monier-Faugere MC, Geng Z, et al. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos Int. 1998;8:274-281.
28. Anderson JJB, Ambrose WW, Garner SC. Biphasic effects of genistein on bone tissue in the ovariectomized, lactating rat model. Proc Soc Exp Biol Med. 1998;217:345-350.
29. Malochet S, Picherit C, Horcajada-Molteni MN, et al. Do endurance training and soy isoflavones exhibit additive effects on ovariectomy-induced osteopenia in the rat? [abstract]. J Bone Miner Res. 1999;14(suppl 1):S536.
30. Arjmandi BH, Birnbaum R, Goyal NV, et al. Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. Am J Clin Nutr. 1998;68(suppl):1364S-1368S.
31. Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol. 1997;17:3392-3398.
32. Anderson JW, Johnstone BM, Cooke-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Eng J Med. 1995;333:276-281.
33. Baum JA, Teng H, Erdman JW Jr, et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr. 1998;68:545-551.
34. Crouse JR III, Morgan T, Terry JG, et al. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med. 1999;159:2070-2076.
35. Wangen KE, Duncan AM, Xu X, et al. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am J Clin Nutr. 2001;73:225-231.
36. Anthony MS, Clarkson TB, Hughes CL Jr, et al. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J Nutr. 1996;126:43-50.
37. Greaves KA, Parks JS, Williams JK, et al. Intact dietary soy protein, but not adding an isoflavone-rich soy extract to casein, improves plasma lipids in ovariectomized cynomolgus monkeys. J Nutr. 1999;129:1585-1592.
38. Simons LA, von Konigsmark M, Simons J, et al. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol. 2000;85:1297-1301.
39. Mackey R, Ekangaki A, Eden JA. The effects of soy protein in women and men with elevated plasma lipids. Biofactors. 2000;12:251-257.
40. Sirtori CR, Gianazza E, Manzoni C, et al. Role of isoflavones in the cholesterol reduction by soy proteins in the clinic [letter]. Am J Clin Nutr. 1997;65:166-167.
41. Howes JB, Sullivan D, Lai N, et al. The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolaemia. Atherosclerosis. 2000;152:143-147.
42. Albertazzi P, Pansini F, Bonaccorsi G, et al. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol. 1998;91:6-11.
43. Murkies AL, Lombard C, Strauss BJ, et al. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas. 1995;21:189-195.
44. Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause. 2000;7:105-111.
45. Brzezinski A, Adlercreutz H, Shaoul R, et al. Short-term effects of phytoestrogen-rich diet on postmenopausal women. Menopause. 1997;4:89-94.
46. Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause. 2000;7:105-111.
47. Washburn S, Burke GL, Morgan T, et al. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause. 1999;6:7-13.
48. St. Germain A, Peterson CT, Robinson JG, et al. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause. 2001;8:17-26.
49. Baber RJ, Templeman C, Morton T, et al. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric. 1999;2:85-92.
50. Knight DC, Howes JB, Eden JA. The effect of Promensil™, an isoflavone extract, on menopausal symptoms. Climacteric. 1999;2:79-84.
51. Potter SM, Baum JA, Teng H, et al. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68(suppl 6):1375S-1379S.
52. Alekel DL, St. Germain A, Peterson CT, et al. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr. 2000;72:844-852.
53. Harrison E, Adjei A, Ameho C, et al. The effect of soybean protein on bone loss in a rat model of postmenopausal osteoporosis. J Nutr Sci Vitaminol (Tokyo). 1998;44:257-268.
54. Fanti O, Faugere MC, Gang Z, et al. Systematic administration of genistein partially prevents bone loss in ovariectomized rats in a nonestrogen-like mechanism [abstract]. Am J Clin Nutr. 1998;68(suppl):1517S-1518S.
55. Arjmandi BH, Alekel L, Hollis BW, et al. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr. 1996;126:161-167.
56. Fanti P, Monier-Faugere MC, Geng Z, et al. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos Int. 1998;8:274-281.
57. Anderson JJB, Ambrose WW, Garner SC. Biphasic effects of genistein on bone tissue in the ovariectomized, lactating rat model. Proc Soc Exp Biol Med. 1998;217:345-350.
58. Malochet S, Picherit C, Horcajada-Molteni MN, et al. Do endurance training and soy isoflavones exhibit additive effects on ovariectomy-induced osteopenia in the rat? [abstract]. J Bone Miner Res. 1999;14(suppl 1):S536.
59. Arjmandi BH, Birnbaum R, Goyal NV, et al. Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. Am J Clin Nutr. 1998;68(suppl):1364S-1368S.
60. Lees CJ, Ginn TA. Soy protein isolate diet does not prevent increased cortical bone turnover in ovariectomized macaques. Calcif Tissue Int. 1998;62:557-558.
61. Jayo MJ. Dietary soy isoflavones and bone loss: a study in ovariectomized monkeys [abstract]. J Bone Miner Res. 1996;11(suppl 1):S228.
62. Gallagher JC, Rafferty K, Haynatzka V, et al. The effect of soy protein on bone metabolism [abstract]. J Nutr. 2000;130:667S.
63. Fanti O, Faugere MC, Gang Z, et al. Systematic administration of genistein partially prevents bone loss in ovariectomized rats in a nonestrogen-like mechanism [abstract]. Am J Clin Nutr. 1998;68(suppl):1517S-1518S.
64. Fanti P, Monier-Faugere MC, Geng Z, et al. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos Int. 1998;8:274-281.
65. Crowell JA, Levine BS, Page JG, et al. Preclinical safety studies of isoflavones [abstract]. J Nutr. 2000;130(suppl):677S.
66. Jenkins DJ, Kendall CW, Jackson CJ, et al. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am J Clin Nutr. 2002;76:365-372.
67. Proceedings and abstracts. 3rd International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. Washington DC, USA. October 31-November 3, 1999. J Nutr. 2000;130:653S-711S.
68. Hilakivi-Clarke L, Cho E, Onojafe I, et al. Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. Oncol Rep. 1999;6:1089-1095.
69. Martini MC, Dancisak BB, Haggans CJ, et al. Effects of soy intake on sex hormone metabolism in premenopausal women. Nutr Cancer. 1999;34:133-139.
70. Maskarinec G, Franke AA, Williams AE, et al. The effects of an isoflavone intervention on the reproductive cycle of premenopausal women. Presented at: European Conference on Nutrition & Cancer; June 21-24, 2001; Lyon, France.
71. Divi RL, Chang HC, Doerge DR. Anti-thyroid isoflavones from soybean: isolation, characterization, and mechanisms of action. Biochem Pharmacol. 1997;54:1087-1096.
72. Chorazy PA, Himelhoch S, Hopwood NJ, et al. Persistent hypothyroidism in an infant receiving a soy formula: case report and review of the literature. Pediatrics. 1995;96(1 pt 1):148-150.
73. Jabbar MA, Larrea J, Shaw RA. Abnormal thyroid function tests in infants with congenital hypothyroidism: the influence of soy-based formula. J Am Coll Nutr. 1997;16:280-282.
74. Ingram DM, Hickling C, West L, et al. The Breast.
75. Allred CD, Allred KF, Ju YH, et al. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 2001;61:5045-5050.
76. Ju YH, Allred CD, Allred KF, et al. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr. 2001;131:2957-2962.
77. Allred CD, Ju YH, Allred KF, et al. Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis. 2001;22:1667-1673.
78. Cassidy A, Bingham S, Setchell KDR. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr. 1994;60:333-340.
79. Persky VW, et al. Effect of soy protein on endogenous hormones in postmenopausal women. Am J Clin Nutr. 2002;75:145-153.
80. Lu LJW, Anderson KE, Grady JJ, Nagamani M. Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prev. 1996;5:63-70.
81. Duncan AM, Underhill KEW, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab. 1999;84:3479-3484.
82. Xu X, Duncan AM, Merz BE, Kurzer MS. Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women. Cancer Epidemiol Biomarkers Prev. 1998;7:1101-1108.
83. Dewell A, Hollenbeck CB, Bruce B. The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. J Clin Endocrinol Metab. 2002;87:118-121.
84. Sirtori CR, Bosisio R, Pazzucconi F, et al. Soy milk with a high glycitein content does not reduce low-density lipoprotein cholesterolemia in type II hypercholesterolemic patients. Ann Nutr Metab. 2002;46:88-92
85. Yellayi S, Naaz A, Szewczykowski MA, et al. The phytoestrogen genistein induces thymic and immune changes: A human health concern? Proc Natl Acad Sci USA. 2002;99:7616-7621.
86. Zoppi G, Guandalini S. The story of soy formula feeding in infants: a road paved with good intentions. J Pediatr Gastroenterol Nutr. 1999;28:541-543.
87. Zoppi G, Mantovanelli F, Pittschieler K, Delem A, Teuwen DE. Response to RIT 4237 oral rotavirus vaccine in human milk, adapted- and soy-formula fed infants. Acta Paediatr Scand. 1989;78:759-762.
88. Zoppi G. Soy milk feeding and the immune system. Lancet. 1983;2:861.
89. Zoppi G, Zamboni G, Bassani N, Vazzoler G. Gammaglobulin level and soy-protein intake in early infancy. Eur J Pediatr. 1979;131:61-69.
90. Kotsopoulos D, Dalais FS, Liang YL, et al. The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. Climacteric. 2000;3:161-167.
91. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 2002;20:1449-1455.
92. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer. 2002;94:1166-1174.
93. Maskarinec G, Williams AE, Inouye JS, et al. A randomized isoflavone intervention among premenopausal women. Cancer Epidemiol Biomarkers Prev. 2002;11:195-201.
94. Lu LJ, Anderson KE, Grady JJ, et al. Effects of soy consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prev. 1996;5:63-70.
95. van de Weijer P, Barentsen R. Isoflavones from red clover (Promensil®) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas. 2002;42:187.
96. Messina M, Gardner C, Barnes S. Gaining insight into the health effects of soy but a long way still to go: commentary on the Fourth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. J Nutr. 2002;132:547S-551S.
97. Hargreaves DF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab. 1999;84:4017-4024.
98. Bell DS, Ovalle F. Use of soy protein supplement and resultant need for increased dose of levothyroxine. Endocr Pract. 2001;7:193-194.
99. Doerge DR, Sheehan DM. Goitrogenic and estrogenic activity of soy isoflavones. Environ Health Perspect. 2002;110(suppl 3):349-353.
100. Chang HC, Doerge DR. Dietary genistein inactivates rat thyroid peroxidase in vivo without an apparent hypothyroid effect. Toxicol Appl Pharmacol. 2000;168:244-252.
101. Duncan AM, Merz BE, Xu X, et al. Soy isoflavones exert modest hormonal effects in premenopausal women. J Clin Endocrinol Metab. 1999;84:192-197.
102. Balmir F, Staack R, Jeffrey E, et al. An extract of soy flour influences serum cholesterol and thyroid hormones in rats and hamsters. J Nutr. 1996;126:3046-3053.
103. Potter SM, Pertile J, Berber-Jimenez MD Soy protein concentrate and isolated soy protein similarly lower blood serum cholesterol but differently affect thyroid hormones in hamsters. J Nutr. 1996;126:2007-2011.
104. Forsythe WA 3rd. Soy protein, thyroid regulation and cholesterol metabolism. J Nutr. 1995;125(suppl 3):619S-623S.
105. White LR, Petrovitch H, Ross GW, et al. Brain aging and midlife tofu consumption. J Am Coll Nutr. 2000;19:242-255.
106. Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause. 2002;9:329-334.
107. Quella SK, Loprinzi CL, Barton DL, Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol. 2000;18:1068-1074.
108. Sanders TA, Dean TS, Grainger D, et al. Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor beta(1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. Am J Clin Nutr. 2002;76:373-377.
109. Nakamura Y, Tsuji S, Tonogai Y. Determination of the levels of isoflavonoids in soybeans and soy-derived foods and estimation of isoflavonoids in the Japanese daily intake. J AOAC Int. 2000;83:635-650.
110. Yeung J, Yu TF. Effects of isoflavones (soy phyto-estrogens) on serum lipids: a meta-analysis of randomized controlled trials. Nutr J. 2003 Nov 19. [Epub ahead of print]
111. Crisafulli A, Marini H, Bitto A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004;11:400-404.
112. Chiechi LM, Putignano G, Guerra V, et al. The effect of a soy rich diet on the vaginal epithelium in postmenopause: a randomized double blind trial. Maturitas. 2003;45:241-246.
113. Messina M, Hughes C. Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. J Med Food. 2003;6:1-11.
114. Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: The Isoflavone Clover Extract (ICE) Study. JAMA. 2003;290:207-214.
115. Penotti M, Fabio E, Modena AB, et al. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril. 2003;79:1112-1117.
116. Secreto G, Chiechi LM, Amadori A, et al. Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, double-blind, randomized study. Maturitas 2004;47:11-20.
117. Nikander E, Kilkkinen A, Metsa-Heikkila M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol. 2003;101:1213-1220.
118. Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, et al. Soymilk or progesterone for prevention of bone loss. A 2 year randomized, placebo-controlled trial. Eur J Nutr. 2004 Apr 14. [Epub ahead of print]
119. Dalais FS, Ebeling PR, Kotsopoulos D, et al. The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clin Endocrinol (Oxf). 2003;58:704-709.
120. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women. JAMA. 2004;292:65-74.
121. Yoles I, Yogev Y, Frenkel Y, et al. Tofupill/Femarelle (DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss. Menopause. 2003;10:522-525
122. Chen YM, Ho SC, Lam SS, et al. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J Clin Endocrinol Metab. 2003;88:4740-4747.
123. Cotter A, Cashman KD. Genistein appears to prevent early postmenopausal bone loss as effectively as hormone replacement therapy. Nutr Rev. 2003;61:346-351.
124. Atkinson C, Compston JE, Day NE, et al. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2004;79:326-333.
125. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004;59:141-147.
126. Adams KF, Chen C, Newton KM, et al. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2004;13:644-648.
127. Hoie LH, Morgenstern EC, Gruenwald J, et al. A double-blind placebo-controlled clinical trial compares the cholesterol lowering effects of two different soy protein preparations in hypercholesterolemic subjects. Eur J Nutr. 2004 Apr 5. [Epub ahead of print]
128. Nestel P, Cehun M, Chronopoulos A, et al. A biochanin-enriched isoflavone from red clover lowers LDL cholesterol in men. Eur J Clin Nutr. 2004;58:403-408.
129. Meyer BJ, Larkin TA, Owen AJ, et al. Limited lipid-lowering effects of regular consumption of whole soybean foods. Ann Nutr Metab. 2004;48:67-78.
130. Crisafulli A, Marini H, Bitto A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004;11:400-404.
131. Chiechi LM, Putignano G, Guerra V, et al. The effect of a soy rich diet on the vaginal epithelium in postmenopause: a randomized double blind trial. Maturitas. 2003;45:241-246.
132. Messina M, Hughes C. Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. J Med Food. 2003;6:1-11.
133. Baber RJ, Templeman C, Morton T, et al. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric. 1999;2:85-92.
134. Knight DC, Howes JB, Eden JA. The effect of Promensil™, an isoflavone extract, on menopausal symptoms. Climacteric. 1999;2:79-84.
135. Teede HJ, Dalais FS, McGrath BP. Dietary soy containing phytoestrogens does not have detectable estrogenic effects on hepatic protein synthesis in postmenopausal women. Am J Clin Nutr. 2004;79:396-401.
136. Zittermann A, Geppert J, Baier S, et al. Short-term effects of high soy supplementation on sex hormones, bone markers, and lipid parameters in young female adults. Eur J Nutr. 2004;43:100-108. Epub 2004 Jan 6.
137. Maskarinec G, Williams AE, Inouye JS, et al. A randomized isoflavone intervention among premenopausal women. Cancer Epidemiol Biomarkers Prev. 2002;11:195-201.
138. Teede HJ, Dalais FS, Kotsopoulos D, et al. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab. 2001;86:3053-3060.
139. Atkinson C, Warren RM, Sala E, et al. Red clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]. Breast Cancer Res. 2004;6:R170-R179. Epub 2004 Feb 24.
140. Penotti M, Fabio E, Modena AB, et al. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril. 2003;79:1112-1117.
141. Balk JL, Whiteside DA, Naus G, et al. A pilot study of the effects of phytoestrogen supplementation on postmenopausal endometrium. J Soc Gynecol Invest. 2002;9:238-242.
142. Unfer V, Casini ML, Costabile L, et al. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2004;82:145-148.
143. Bruce B, Messina M, Spiller GA. Isoflavone supplements do not affect thyroid function in iodine-replete postmenopausal women. J Med Food. 2003;6:309-316.
144. Howes JB, Bray K, Lorenz L, et al. The effects of dietary supplementation with isoflavones from red clover on cognitive function in postmenopausal women. Climacteric. 2004;7:70-77.
145. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women. JAMA. 2004;292:65-74.
146. Duffy R, Wiseman H, File SE. Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones. Pharmacol Biochem Behav. 2003;75:721-729.
147. Crisafulli A, Altavilla D, Marini H, et al. Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. Menopause. 2005;12:186-192.
148. Cheng SY, Shaw NS, Tsai KS, et al. The hypoglycemic effects of soy isoflavones on postmenopausal women. J Womens Health (Larchmt). 2005;13:1080-1086.
149. Macgregor CA, Canney PA, Patterson G, et al. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer. 2005;41:708-714.
150. Harkness LS, Fiedler K, Sehgal AR, et al. Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. J Womens Health (Larchmt). 2005;13:1000-1007.
151. Mori M, Aizawa T, Tokoro M, et al. Soy isoflavone tablets reduce osteoporosis risk factors and obesity in middle-aged Japanese women. Clin Exp Pharmacol Physiol. 2005;31(suppl 2):S39-41.
152. Unfer V, Casini ML, Gerli S, et al. Phytoestrogens may improve the pregnancy rate in in vitro fertilization-embryo transfer cycles: a prospective, controlled, randomized trial. Fertil Steril. 2004;82:1509-1513.
153. Goldin BR, Brauner E, Adlercreutz H, et al. Hormonal response to diets high in soy or animal protein without and with isoflavones in moderately hypercholesterolemic subjects. Nutr Cancer. 2005;51:1-6.
154. File SE, Hartley DE, Elsabagh S, et al. Cognitive improvement after 6 weeks of soy supplements in postmenopausal women is limited to frontal lobe function. Menopause. 2005;12:193-201.
155. Kok L, Kreijkamp-Kaspers S, Grobbee DE, et al. A randomized, placebo-controlled trial on the effects of soy protein containing isoflavones on quality of life in postmenopausal women. Menopause. 2005;12:56-62.
156. Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr. 2005;81:397-408.
157. Uesugi S, Watanabe S, Ishiwata N, et al. Effects of isoflavone supplements on bone metabolic markers and climacteric symptoms in Japanese women. Biofactors. 2005;22:221-228.
158. Kreijkamp-Kaspers S, Kok L, Grobbee DE et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized, controlled trial. Obstet Gynecol Surv. 2004;60:41-43.
159. Macgregor CA, Canney PA, Patterson G, et al. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer. 2005;41:708-714.
160. Harkness LS, Fiedler K, Sehgal AR, et al. Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. J Womens Health (Larchmt). 2005;13:1000-1007.
161. Mori M, Aizawa T, Tokoro M, et al. Soy isoflavone tablets reduce osteoporosis risk factors and obesity in middle-aged Japanese women. Clin Exp Pharmacol Physiol. 2005;31(suppl 2):S39-41.
162. Nikander E, Rutanen EM, Nieminen P, et al. Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women. Fertil Steril. 2005;83:137-142.
163. Liu B, Edgerton S, Yang X, et al. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res. 2005;65:879-886.
164. Goldin BR, Brauner E, Adlercreutz H, et al. Hormonal response to diets high in soy or animal protein without and with isoflavones in moderately hypercholesterolemic subjects. Nutr Cancer. 2005;51:1-6.
165. Dillingham BL, McVeigh BL, Lampe JW, et al. Soy protein isolates of varying isoflavone content exert minor effects on serum reproductive hormones in healthy young men. J Nutr. 2005;135:584-591.
166. Manonai J, Songchitsomboon S, Chanda K, et al. The effect of a soy-rich diet on urogenital atrophy: A randomized, cross-over trial. Maturitas. 2005 Nov 15. [Epub ahead of print]
167. Hidalgo LA, Chedraui PA, Morocho N, et al. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: A randomized, double-blind, placebo-controlled study. Gynecol Endocrinol. 2005;21:257-264.
168. Wood CE, Register TC, Franke AA, et al. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res. 2006;66:1241-1249.
169. Bryant M, Cassidy A, Hill C, et al. Effect of consumption of soy isoflavones on behavioural, somatic and affective symptoms in women with premenstrual syndrome. Br J Nutr. 2005;93:731-739.
170. Casini ML, Marelli G, Papaleo E, et al. Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: a randomized, double-blind, crossover, placebo-controlled study. Fertil Steril. 2006;85:972-978.
171. Reimann M, Dierkes J, Carlsohn A, et al. Consumption of soy isoflavones does not affect plasma total homocysteine or asymmetric dimethylarginine concentrations in healthy postmenopausal women. J Nutr. 2005;136:100-105.
172. McVeigh BL, Dillingham BL, Lampe JW, et al. Effect of soy protein varying in isoflavone content on serum lipids in healthy young men. Am J Clin Nutr. 2006;83:244-251.
173. Manonai J, Songchitsomboon S, Chanda K, et al. The effect of a soy-rich diet on urogenital atrophy: A randomized, cross-over trial. Maturitas. 2005 Nov 15. [Epub ahead of print]
174. Verhoeven MO, van der Mooren MJ, van de Weijer PH, et al. Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause. 2005 Jul 1. [Epub ahead of print]
175. Huang HY, Yang HP, Yang HT, et al. One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. J Nutr Biochem. 2006 Feb 3. [Epub ahead of print]
176. Wu J, Oka J, Higuchi M, et al. Cooperative effects of isoflavones and exercise on bone and lipid metabolism in postmenopausal Japanese women: a randomized placebo-controlled trial. Metabolism. 2006;55:423-433.
177. Nettleton JA, Greany KA, Thomas W, et al. Short-term soy and probiotic supplementation does not markedly affect concentrations of reproductive hormones in postmenopausal women with and without histories of breast cancer. J Altern Complement Med. 2006;11:1067-1074.
178. Imhof M, Gocan A, Reithmayr F, et al. Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women. Maturitas. 2006 Feb 28. [Epub ahead of print]
179. Imhof M, Gocan A, Reithmayr F, et al. Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women. Maturitas 2006 Feb 28. [Epub ahead of print]
180. Hutchins AM, McIver IE, Johnston CS, et al. Hypertensive crisis associated with high dose soy isoflavone supplementation in a post-menopausal woman: a case report [ISRCTN98074661]. BMC Womens Health. 2005 Jun 23. [Epub ahead of print]
181. D'Anna R, Cannata ML, Atteritano M, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study. Menopause. 2007 Jan 23. [Epub ahead of print]
182. Ho SC, Chan AS, Ho YP, et al. Effects of soy isoflavone supplementation on cognitive function in Chinese postmenopausal women: a double-blind, randomized, controlled trial. Menopause. 2007 Feb 15. [Epub ahead of print]
183. Ma DF, Qin LQ, Wang PY, et al. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2007 Mar 28. [Epub ahead of print]
184. Ho SC, Chen YM, Ho SS, et al. Soy isoflavone supplementation and fasting serum glucose and lipid profile among postmenopausal Chinese women: A double-blind, randomized, placebo-controlled trial. Menopause. 2007 Mar 19. [Epub ahead of print]
185. Sites CK, Cooper BC, Toth MJ, et al. Effect of a daily supplement of soy protein on body composition and insulin secretion in postmenopausal women. Fertil Steril. 2007 Apr 3. [Epub ahead of print]
186. Fournier LR, Ryan Borchers TA, Robison LM, et al. The effects of soy milk and isoflavone supplements on cognitive performance in healthy, postmenopausal women. J Nutr Health Aging. 2007;11:155-164.
187. Izumi T, Saito M, Obata A, et al. Oral intake of soy isoflavone aglycone improves the aged skin of adult women. J Nutr Sci Vitaminol (Tokyo). 2007;53:57-62.
188. Teas J, Braverman LE, Kurzer MS, et al. Seaweed and soy: companion foods in asian cuisine and their effects on thyroid function in american women. J Med Food. 2007;10:90-100.
189. Wu J, Oka J, Ezaki J, et al. Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause. 2007 Apr 25. [Epub ahead of print]
190. Atteritano M, Marini H, Minutoli L, et al. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a 2-years randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007 May 22. [Epub ahead of print]
191. Marini H, Minutoli L, Polito F, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women. Ann Intern Med. 2007;146:839-847.
192. Khaodhiar L, Ricciotti HA, Li L, et al. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause. 2007 Jul 18. [Epub ahead of print]
193. Clerici C, Setchell KD, Battezzati PM, et al. Pasta naturally enriched with isoflavone aglycons from soy germ reduces serum lipids and improves markers of cardiovascular risk. J Nutr. 2007;137:2270-2278.
194. Hamilton-Reeves JM, Rebello SA, Thomas W, et al. Soy protein isolate increases urinary estrogens and the ratio of 2:16-hydroxyestrone in men at high risk of prostate cancer. J Nutr. 2007;137:2258-2263.
195. Gardner CD, Messina M, Kiazand A, et al. Effect of two types of soy milk and dairy milk on plasma lipids in hypercholesterolemic adults: a randomized trial. J Am Coll Nutr. 2007;26:669-677.
196. Manonai J, Chittacharoen A, Theppisai U, et al. Effect of Pueraria mirifica on vaginal health. Menopause. 2007 Mar 30.
197. Chandeying V, Sangthawan M. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study. J Med Assoc Thai. 2007;90:1720-1726.
198. Khaodhiar L, Ricciotti HA, Li L, et al. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause. 2008;15:125-32.
199. Brink E, Coxam V, Robins S, et al. Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study. Am J Clin Nutr. 2008;87:761-770.
200. Jou HJ, Wu SC, Chang FW, et al. Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones. Int J Gynaecol Obstet. 2008 Apr 4.
201. Trifiletti A, Gaudio A, Lasco A, et al. Haemostatic effects of phytoestrogen genistein in postmenopausal women. Thromb Res. 2008 Apr 12.
202. Pop EA, Fischer LM, Coan AD, et al. Effects of a high daily dose of soy isoflavones on DNA damage, apoptosis, and estrogenic outcomes in healthy postmenopausal women: a phase I clinical trial. Menopause. 2008 Apr 28.
203. Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: Analysis and commentary. Nutr J. 2008 Jun 3.
204. Torella M, Tammaro C, Auriemma S, et al. Endometrial survey during phytoestrogens therapy in postmenopausal women. Minerva Ginecol. 2008;60:281-285.
205. Thorp AA, Howe PR, Mori TA, et al. Soy food consumption does not lower LDL cholesterol in either equol or nonequol producers. Am J Clin Nutr. 2008;88:298-304.
206. Kurzer MS. Soy consumption for reduction of menopausal symptoms. Inflammopharmacology. 2008 Sep 26. [Epub ahead of print]
207. Rios DR, Rodrigues ET, Cardoso AP, et al. Lack of effects of isoflavones on the lipid profile of Brazilian postmenopausal women. Nutrition. 2008;24:1153-1158.
208. van Die MD, Bone KM, et al. Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials. BJU Int. 2014;113(5b):E119-E130.
209. Cheng PF, Chen JJ, et al. Do soy isoflavones improve cognitive function in postmenopausal women? A meta-analysis. Menopause. 2014 Jul 7 [Epub ahead of print].
Last reviewed December 2015 by EBSCO CAM Review Board Last Updated: 12/15/2015